CME/CE PODCAST: Recognizing the Burden of Residual Symptoms in MDD

06/27/24 • 29 min

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/recognizing-the-burden-of-residual-symptoms-in-mdd-9526
Summary
Early and effective treatment of major depressive disorder (MDD) is essential to prevent persistent residual symptoms, which are associated with worse outcomes. Evidence indicates that residual symptoms, such as impaired cognition, are underrecognized and undertreated in routine clinical care. Recognizing residual symptoms and the factors contributing to suboptimal treatment response is a critical first step to modifying management, with the goal of eliminating residual symptoms and achieving full remission.
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss common residual symptoms and other signs of suboptimal treatment response, including the impact of antidepressant side effects and the efficacy of antidepressants for residual symptoms.

This podcast/webcast was recorded and is being used with permission of the presenters.
This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.25 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Previous Episode

CME/CE Deep Dive into 5: Answering Your Questions on Lipids and Risk

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/answering-your-questions-on-lipids-and-risk-9498
Summary
There’s no shortage of information on the management of lipids for the prevention of cardiovascular disease:

2018 Guideline on the Management of Blood Cholesterol.
2022 ACC Expert Consensus Decision Pathway.
CLEAR Outcomes, CVOT studies, Risk Calculators.

Helping sort these and other topics out, Dr. James Underberg and Dr. Jessica Pena discuss the top 5 learner submitted questions/topics from the recent programs on non-statin lipid management in primary prevention of ASCVD.
Learning Objectives
Upon completion of this activity, learners should be able to:

Identify patients at high risk for ASCVD, based on risk factors and testing, who would benefit from additional lipid lowering
Integrate evolving evidence with guidelines and expert recommendations in the use of non-statin therapies for primary prevention of ASCVD in patients at high risk

This activity is accredited for CME/CE Credit
Association of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Association of Black Cardiologists, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported in part by an educational grant from Esperion Therapeutics, Inc. and an independent educational grant from Novartis Pharmaceuticals Corporation.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Next Episode

CME/CE Podcast: A Better Understanding: Advances in Severe Asthma

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/a-better-understanding-advances-in-severe-asthma-9530
Summary
In this CME/CE podcast, join NACE and the Association for Pulmonary Advanced Practice Providers as Nurse Practitioner Corinne Young and Dr. Diego Maselli take a deep dive into the latest advances in severe asthma treatment. Join in a dynamic discussion on groundbreaking research into IL-13 agents and mucus production, TSLP, mast cell activity, and more. Discover the experts’ take on the latest evolutions in our understanding of asthma treatments, and gain practical insights into how these innovations are shaping clinical practice.
Learning Objectives
Upon completion of this activity, learners should be able to:

Review evolving concepts in the understanding, evaluation, and treatments of severe asthma and their implications on management

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0 hours of pharmacology.
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.